Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Catherine Alonzo Catherine Alonzo Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
Heidelberg Transforming Science Day 2025 - Save the Date Heidelberg Transforming Science Day 2025 - Save the Date The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.
Ranking in the top 25% in EcoVadis Sustainability Assessment Ranking in the top 25% in EcoVadis Sustainability Assessment Boehringer Ingelheim has received a silver medal from EcoVadis in the 2023 sustainability assessment, including above industry average scores.
Combination Therapy Combination Therapy It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Jens Barthelmes Jens Barthelmes My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Meet the BD&L Team 2019 Meet the BD&L Team 2019 Hear from our team and find out more about our approach to partnering.
Partnering in Biotherapeutics HP OCTOBER 2024 CORP_1.pdf Partnering in Biotherapeutics HP OCTOBER 2024 CORP_1.pdf
CT-155: Prescription digital therapeutic CT-155: Prescription digital therapeutic CT-155: Prescription digital therapeutic
The ANGELS infographic showcasing global stroke care improvements.pdf The ANGELS infographic showcasing global stroke care improvements.pdf
Pet parasites are still here. What's the risk? Pet parasites are still here. What's the risk? What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
Patient Documentary Patient Documentary People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
Rabisin® / Raboral V-RG® Rabisin® / Raboral V-RG® Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
global-top-employer global-top-employer For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
STOP Rabies: moving towards elimination STOP Rabies: moving towards elimination Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Research Beyond Borders overview Research Beyond Borders overview Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Biberach Biberach The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
NeO - smart and sustainable vaccines NeO - smart and sustainable vaccines The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Sharing knowledge from our medical device development Sharing knowledge from our medical device development Why do we share some of our work beyond Boehringer for free?